Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-11-25 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物关于签订日常经营性长单采购合同的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a supplementary long-term procurement contract for raw materials between the company and a supplier. It details contract terms, background, risks, and impact on the company. There is no financial report, earnings data, or management discussion. The document is a formal disclosure of a business contract, typical of capital or financing updates related to procurement and cost control. It is not an annual or interim report, audit, or earnings release. The document length is short (1832 characters), and it is a direct announcement, not a report publication notice or certification. Therefore, the best fitting category is Capital/Financing Update (CAP).
2022-11-25 Chinese
前沿生物自愿披露关于雾化吸入用FB2001获批开展ⅡⅢ期临床试验的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a company about the approval to conduct Phase II/III clinical trials for a drug candidate. It includes details about the drug, its intended use, and some preclinical study results. There are no financial statements, earnings data, or detailed management analysis. The document is relatively short (1385 characters) and serves as a regulatory announcement about clinical trial approval rather than a financial or management report. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is an official announcement related to regulatory approval and clinical trial progress, which aligns best with Regulatory Filings (RNS) as a general category for such disclosures that do not fit other specific categories.
2022-11-23 Chinese
国浩律师（南京）事务所关于前沿生物药业（南京）股份有限公司2022年第一次临时股东大会的法律意见书
Regulatory Filings
2022-11-11 Chinese
前沿生物2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement from the company's first extraordinary general meeting of shareholders in 2022. It details the meeting date, attendance, voting results on specific proposals, and legal witness statements confirming the validity of the meeting and voting process. There is no financial data or report content included, only the official announcement of the voting results and meeting resolutions. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes rather than the full report or financial statements.
2022-11-11 Chinese
前沿生物2022年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2022 First Extraordinary General Meeting" of the company. It contains detailed meeting instructions, agenda, and proposals for shareholder voting, including the appointment of the 2022 financial report audit firm. The content is focused on the meeting logistics, voting procedures, and agenda items rather than the actual financial report or audit report itself. The document length is 3791 characters, which is relatively short and consistent with meeting materials rather than a full report. There is no substantive financial data or audit results included, only the proposal to appoint auditors. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. Therefore, the document should be classified as AGM Information (AGM-R).
2022-11-02 Chinese
前沿生物关于召开2022年第三季度业绩说明会的公告
Investor Presentation Classification · 85% confidence The document is an announcement about the scheduling and details of a 2022 third quarter earnings explanation meeting (业绩说明会). It mentions the date, time, location, and format of the meeting, as well as how investors can participate and ask questions. It references the previously released 2022 third quarter report but does not contain any financial data or analysis itself. The document is short (1470 characters) and serves to inform investors about the upcoming earnings call event rather than presenting the earnings report or transcript. Therefore, it is best classified as a Call Transcript announcement or related to an earnings call event. However, since it is only an announcement of the meeting and not the transcript itself, the closest fitting category is Investor Presentation (IP) or Regulatory Filings (RNS). Given the detailed description of the meeting and investor interaction, Investor Presentation (IP) is the most appropriate classification here, with moderate confidence due to the nature of the announcement being about an investor meeting focused on financial results.
2022-11-02 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.